Switzer launches 'Move for Mental Health'
VIGO COUNTY, Ind. (WTWO/WAWV) — May is Mental Health Awareness month and Vigo County Commissioner Chris Switzer is encouraging residents to step outside, get active, and join the conversation about mental health through a new initiative: Move for Mental Health – #StridesWithSwitzer.
Throughout the month of May, Switzer will host weekly walks every Monday at 6 PM at Dewey Point in West Terre Haute. These walks aim to promote physical movement, boost mental well-being, and strengthen community connections.
'We often talk about physical health, but mental health is just as important—and too often overlooked,' said Commissioner Switzer. 'Walking together is a simple way to start the conversation, support each other, and help break the stigma around mental health.'
In addition to the walks, Commissioner Switzer is launching a social media campaign using the hashtag #StridesWithSwitzer, inviting residents to share their own stories, walking routes, and reflections on how movement helps improve their mood, reduce stress, and foster connection.
Participants are encouraged to join the walks, engage online, and take small steps toward better mental health—both for themselves and their community.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on Cardinal Health: 'I am a Believer'
Cardinal Health, Inc. (NYSE:CAH) is one of the 11 stocks on Jim Cramer's radar. Calling Cardinal Health, Inc.'s (NYSE:CAH) upcoming Investor Day a possible needle mover, Cramer said: 'Now, Thursday brings some analyst meetings that could move the needle. Cardinal Health, we've had them on a couple of times, tells a terrific story about how it's much more than a drug middleman. And I believe, I am a believer.' A senior physician in a modern healthcare institution administering medication to a patient. Cardinal Health (NYSE:CAH) provides medical products and services used in various care settings. The company delivers pharmaceuticals, equipment, and support tools while managing distribution, logistics, and pharmacy operations through healthcare-focused technology. On May 14, Cramer extensively commented on the company as he said: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
